Evidence map›Paper›PMID 36336123›Full record

ArticleThe Journal of allergy and clinical immunology2023

Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective.

Chrysanthi Skevaki, R Sharon Chinthrajah, Daria Fomina, Gernot Rohde, Shu Cao, Ziyuan He, Sofia Serdotetskova, Christian Seidemann, Achim Grünewaldt, Abisha Vengadeswaran and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Dog allergen-induced asthma in mice: a relevant model of T2Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 4 countries.

Chrysanthi SkevakiInstitute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, Marburg, Germany; Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, Marburg, Germany. Electronic address: Chrysanthi.Skevaki@uk-gm.de.
R Sharon ChinthrajahSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif.
Daria FominaDepartment of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov University, Moscow, Russia; Moscow City Research and Practical Center of Allergy and Immunology, Clinical State Hospital 52, Moscow Ministry of Healthcare, Moscow, Russia.
Gernot RohdeDepartment of Respiratory Medicine, University Hospital Frankfurt, Frankfurt, Germany; CAPNETZ Foundation, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), the German Center for Lung Research, Hannover, Germany.
Shu CaoSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif.
Ziyuan HeSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif.
Sofia SerdotetskovaMoscow City Research and Practical Center of Allergy and Immunology, Clinical State Hospital 52, Moscow Ministry of Healthcare, Moscow, Russia.
Christian SeidemannDepartment of Data Integration Center, MIRACUM, Philipps University Marburg, Marburg, Germany.
Achim GrünewaldtDepartment of Respiratory Medicine, University Hospital Frankfurt, Frankfurt, Germany.
Abisha VengadeswaranInstitute for Medical Informatics, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt, Germany.
Min XieDepartment of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Antonina KarsonovaDepartment of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov University, Moscow, Russia.
Alexander KaraulovDepartment of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov University, Moscow, Russia.
Kari C NadeauSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif.
Ho-Ryun ChungInstitute for Medical Bioinformatics and Biostatistics, Philipps University Marburg, Marburg, Germany.
Harald RenzInstitute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, Marburg, Germany; Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, Marburg, Germany; Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov University, Moscow, Russia.
Stanford University · USPhilipps University of Marburg · DESechenov University · RUGerman Center for Lung Research · DEGoethe University Frankfurt · DEMinistry of Health of the Russian Federation · RUTongji Hospital · CNUniversities of Giessen and Marburg Lung Center · DEUniversity Hospital Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe global epidemiology of asthma among patients with coronavirus disease 2019 (COVID-19) presents striking geographic differences, defining prevalence zones of high and low co-occurrence of asthma and COVID-19.

objectiveWe aimed to compare asthma prevalence among hospitalized patients with COVID-19 in major global hubs across the world by applying common inclusion criteria and definitions.

methodsWe built a network of 6 academic hospitals in Stanford (Stanford University)/the United States; Frankfurt (Goethe University), Giessen (Justus Liebig University), and Marburg (Philipps University)/Germany; and Moscow (Clinical Hospital 52 in collaboration with Sechenov University)/Russia. We collected clinical and laboratory data for patients hospitalized due to COVID-19.

resultsAsthmatic individuals were overrepresented among hospitalized patients with COVID-19 in Stanford and underrepresented in Moscow and Germany as compared with their prevalence among adults in the local community. Asthma prevalence was similar among patients hospitalized in an intensive care unit and patients hospitalized in other than an intensive care unit, which implied that the risk for development of severe COVID-19 was not higher among asthmatic patients. The numbers of males and comorbidities were higher among patients with COVID-19 in the Stanford cohort, and the most frequent comorbidities among these patients with asthma were other chronic inflammatory airway disorders such as chronic obstructive pulmonary disease.

conclusionThe observed disparity in COVID-19-associated risk among asthmatic patients across countries and continents is connected to the varying prevalence of underlying comorbidities, particularly chronic obstructive pulmonary disease.

Indexed as

AsthmaCOVID-19Pulmonary Disease, Chronic ObstructiveAdultChronic DiseaseComorbidityHospitalizationHumansMaleSARS-CoV-2Chronic airway in inflammation prevalencechronic obstructive pulmonary diseaseCOPDpublic healthSARS-CoV-2

Identifiers

PMID36336123
PMCPMC9632231
OpenAlexW4308486535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.